Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.61 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | IDE | P14735 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19427224 | 1.00 | F2 (0.61) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL18100982 | 0.93 | F2 (0.61) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL22420070 | 0.93 | F2 (0.61) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL18857630 | 0.93 | F2 (0.61) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL18737547 | 0.93 | F2 (0.61) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL25894853 | 0.93 | PRSS1 (0.65) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL17522651 | 0.92 | F2 (0.61) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL18905056 | 0.92 | F2 (0.61) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL20852261 | 0.90 | FOLH1 (0.59) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL23652847 | 0.90 | F2 (0.63) | F2PRSS1PRSS2PRSS3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013755-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-01-19 | — | — | US | disclosed |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-08 | — | — | US | disclosed |
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-02 | — | — | US | disclosed |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| US-10800792-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-13 | — | — | US | disclosed |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-21 | — | — | US | disclosed |
| US-10689396-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-23 | — | — | US | disclosed |
| US-20190284204-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| US-20190276471-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | US | disclosed |
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689396-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | F2 2538/4885PRSS1 3115/4885PRSS2 3907/4885 |
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | F2 2470/4885PRSS1 2847/4885PRSS2 3690/4885 |
| US-20190284204-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | F2 2422/4885PRSS1 3097/4885PRSS2 3798/4885 |
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | F2 2470/4885PRSS1 2847/4885PRSS2 3690/4885 |
| US-20230013755-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, PRKDC | F2 2768/4885PRSS1 2795/4885PRSS2 3491/4885 |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | F2 2538/4885PRSS1 3115/4885PRSS2 3907/4885 |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | F2 2470/4885PRSS1 2847/4885PRSS2 3690/4885 |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | F2 2422/4885PRSS1 3097/4885PRSS2 3798/4885 |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | F2 2626/4885PRSS1 2823/4885PRSS2 3736/4885 |
| US-20190284203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | F2 2422/4885PRSS1 3097/4885PRSS2 3798/4885 |
| US-20190276471-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | F2 2470/4885PRSS1 2847/4885PRSS2 3690/4885 |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | F2 2626/4885PRSS1 2823/4885PRSS2 3736/4885 |
| US-10800792-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, MYLK2 | F2 2422/4885PRSS1 3097/4885PRSS2 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.